Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 15 June 2017

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

DBV Technologies    

Published: 22:30 CEST 15-06-2017 /GlobeNewswire /Source: DBV Technologies / : DBV /ISIN: FR0010417345


AMF REGULATED INFORMATION
Montrouge, France, June 15, 2017

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General

Meeting

 

Shareholders approve all proposed resolutions

 

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today held its Ordinary and Extraordinary General Meeting, which was chaired by Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies.

 

At the General Meeting, the Company's shareholders approved all resolutions submitted by the Board of Directors. These resolutions are posted on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations.

 

 

About DBV Technologies 

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

 

DBV Technologies Contact

Sara Blum Sherman

Director, Investor Relations
+1 212-271-0740
sara.sherman@dbv-technologies.com

 

Media Contact

Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia@webershandwick.com

 

Media Contact Europe

Caroline Carmagnol, Alize RP, Relations Presse

+33 (0)6 64 18 99 59 

caroline@alizerp.com

 



PDF version



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: DBV Technologies, Green Square - Bâtiment D 80/84 rue des Meuniers, Bagneux FR-92220, France
If you would like to unsubscribe and stop receiving these e-mails click here.